Want to see QTRX full AI Analyst Report?
QTRX Stock Chart & Stats
$3.50
-$0.25(-2.12%)
At close: 4:00 PM EST
$3.50
-$0.25(-2.12%)
Day’s Range― - ―
52-Week Range$2.40 - $8.77
Previous CloseN/A
Volume125.22K
Average Volume (3M)509.80K
Market Cap
$172.88M
Enterprise Value$101.44
Total Cash (Recent Filing)$99.27M
Total Debt (Recent Filing)$35.34M
Price to Earnings (P/E)―
Beta1.19
Next Earnings
Aug 10, 2026EPS Estimate
-0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.36
Shares Outstanding47,105,980
10 Day Avg. Volume461,526
30 Day Avg. Volume509,801
Financial Highlights & Ratios
PEG Ratio-0.02
Price to Book (P/B)0.92
Price to Sales (P/S)1.96
P/FCF Ratio-3.40
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.00Price Target Upside14.29% Upside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-1.29
Revenue Forecast (FY)$169.86M
Bulls Say, Bears Say
Bulls Say
Low Leverage & Cash RunwayQuanterix's low leverage and a cash balance near $100M provide a meaningful runway to fund operations, R&D and commercial investments while pursuing cash‑flow breakeven. This reduces near‑term refinancing risk and supports execution of the multi‑quarter plan to stabilize operations.
Large Installed Base & Market LeadershipAn installed base >2,300 instruments and category leadership in ultrasensitive assays create durable recurring revenue from consumables and services. This razor‑and‑blades model underpins long‑term pull‑through and makes instrument placements a strategic asset for sustained revenue generation.
High Unit Economics After SynergiesSustained non‑GAAP gross margins above 49% and realized $85M in cost synergies materially improve unit economics. Higher gross margins and lower structural cost base increase the odds of achieving profitable operations as revenue recovers, making margin sustainability a durable strength.
Bears Say
Persistent Cash BurnLarge negative operating and free cash flows indicate ongoing cash burn that will continue to pressure the balance sheet absent sustained revenue improvement. Even with current cash, multi‑quarter negative OCF increases reliance on external funding or aggressive cost cuts, limiting strategic flexibility.
Significant Organic Demand WeaknessMarked organic declines across core product lines and a sharp drop in pharma revenue reflect structural end‑market headwinds. Persisting weakness in academic and pharma budgets undermines consumables pull‑through and instrument placements, delaying sustainable revenue recovery and stressing growth assumptions.
Deep Net Losses And Eroding EquityLarge, sustained net losses and negative returns on equity have eroded shareholder value and limit internal funding capacity. Continued losses reduce headroom for investment and increase the probability of future dilution or cost containment measures if revenue does not improve.
Quanterix News
QTRX FAQ
What was Quanterix Corporation’s price range in the past 12 months?
Quanterix Corporation lowest stock price was $2.40 and its highest was $8.77 in the past 12 months.
What is Quanterix Corporation’s market cap?
Quanterix Corporation’s market cap is $172.88M.
When is Quanterix Corporation’s upcoming earnings report date?
Quanterix Corporation’s upcoming earnings report date is Aug 10, 2026 which is in 14 days.
How were Quanterix Corporation’s earnings last quarter?
Quanterix Corporation released its earnings results on May 06, 2026. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.513 by $0.143.
Is Quanterix Corporation overvalued?
According to Wall Street analysts Quanterix Corporation’s price is currently Undervalued.
Does Quanterix Corporation pay dividends?
Quanterix Corporation does not currently pay dividends.
What is Quanterix Corporation’s EPS estimate?
Quanterix Corporation’s EPS estimate is -0.41.
How many shares outstanding does Quanterix Corporation have?
Quanterix Corporation has 47,105,980 shares outstanding.
What happened to Quanterix Corporation’s price movement after its last earnings report?
Quanterix Corporation reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.513. Following the earnings report the stock price went down -16.413%.
Which hedge fund is a major shareholder of Quanterix Corporation?
Currently, no hedge funds are holding shares in QTRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Quanterix Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.00 (14.29% Upside)
$4.00 (14.29% Upside)
Hedge Fund Trend
Increased
By 768.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $9.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 3.5%
Last 30 Days ▲ 0.1%
Last 30 Days ▲ 0.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-53.83%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-7.53%
Trailing 12-Months
Company Description
Quanterix Corporation
Quanterix Corporation, based in Billerica, Massachusetts, is a life sciences enterprise dedicated to pioneering and commercializing advanced digital immunoassay platforms. These sophisticated systems are designed to enhance precision health in both scientific research and diagnostic applications, reaching markets across North America, Europe, the Middle East, Africa, and the Asia Pacific regions. The company's core offerings include several innovative instruments: The HD-X instrument, which provides highly sensitive and automated multiplex protein detection. The SR-X instrument, enabling researchers to leverage Simoa detection technology for diverse uses, such as the direct detection of nucleic acids. The SP-X instrument, which utilizes Simoa planar array technology for conducting multiplex chemiluminescent immunoassays. Alongside these platforms, Quanterix also supplies crucial consumables, including assay kits and reagents. In addition to its product line, the company delivers various contract research services, encompassing sample analysis, the development of custom "homebrew" assays, and other specialized research and development projects. Quanterix's operational focus spans critical health areas like neurology, oncology, cardiology, infectious diseases, and inflammation. Its clientele within the life science research sector primarily consists of laboratories affiliated with academic and governmental research institutions, as well as pharmaceutical, biotechnology, and contract research organizations. Sales are managed through a multifaceted approach, combining a direct sales force, dedicated support organizations, and a network of distributors or sales agents. The company was initially incorporated in 2007 as Digital Genomics, Inc., before rebranding to Quanterix Corporation in August of the same year.
QTRX Company Deck
QTRX Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call mixed encouraging operational and financial progress—an increase in reported revenue, strong non-GAAP gross margins above 50%, delivery of $85M in synergies, a healthy cash balance (~$102.6M), and clear strategic investments in commercial capabilities and diagnostics (HD-X IVD push, Tempus partnership). Offsetting these positives are material organic revenue declines (Simoa -21%, spatial -26%), a 33% drop in pharma revenue, softer-than-expected instrumentation sales, and notable one-time acquisition-related charges. Management maintained full-year guidance and outlined concrete steps to drive H2 improvement and cash-flow breakeven, but near-term execution and end-market recovery remain key risks.View all QTRX earnings summariesQTRX Stock 12 Month Forecast
Average Price Target
$4.00
▲(14.29% Upside)
Technical Analysis
Viemed Healthcare
―
Nano-X Imaging
―
Outset Medical
―
908 Devices
―
TriSalus Life Sciences
―
Ownership Overview
6.89% Insiders
19.65% Mutual Funds
1.35% Other Institutional Investors
61.15% Public Companies and
Individual Investors